As the world is eager to return to a normal life after living in a pandemic for more than a year, countries are scrambling to provide vaccines to slow (and hope to stop) the spread of this flu. coronavirus.
The success of this will depend on a range of factors, from manufacturing and shipping billions of drugs to ensuring Rich countries do not monopolize The worldwide supply of vaccines, and crucially, has actually given people the dose.
The chart below will be updated to show the latest data on the largest vaccination campaign in the history of the United States and the world.
There are significant differences in the speed of vaccination from state to state.
The first two vaccines Officially recognized in order to Emergency use In the United States, developed by the company Pfizer/BioNTech with ModernIt is designed to be taken twice every few weeks.This Johnson The vaccine authorized for use in late February requires only one dose. Therefore, vaccination for every person in the United States will ultimately mean 100 to 200 doses of vaccine for every 100 people in every state and territory-a total of between 330 million and 660 million doses in the entire country.it is Huge logistics challenge.
As the Biden administration took over as president and pledged to strengthen the federal government’s deployment of vaccines, the number of daily injections has steadily increased, reaching a peak of more than 3 million doses per day in April. In May, facing the problem of a sharp drop in the number of people killed by gunshots, Biden announced New strategy The aim is to vaccinate difficult-to-reach communities and move from mass vaccination centers to more mobile clinics and pharmacies for appointments.There are still people worried that the vaccination situation will get worse people with Color community behind.
Search or browse in this table to find the status of these key vaccine rollout measures in your state or territory.
Vaccine rollout schedule
This chart shows the number of vaccines administered per 100 people in each state since the beginning of 2021. The country/region numbers of the first three states and the United States are highlighted. Enter the name of any other state or U.S. territory in the search bar and select Add to chart.
This chart shows the daily vaccinations of people who have been vaccinated nationwide since the beginning of 2021. Due to the lag in the report leading to a surge in data, the line showing the 7-day rolling average of vaccines given gives a clearer picture of whether deployment is accelerating or slowing.
Vaccination status in various countries
Show more countries/regions on the map, showing the dose of vaccines per 100 people, because these numbers are more widely reported.
To date, most countries with the highest vaccination rates have very small populations. In terms of vaccine launches, the United States is ahead of most other major countries. Search or browse the table to see the situation in each country.
Vaccine rollout schedule
This chart shows the number of vaccines administered per 100 people in each country/region since the beginning of 2021. Enter the name of any country/region in the search bar and choose to compare its timeline with the top three countries/regions of the United States and other leading global vaccine deployments. Only countries that have started vaccinations will appear.
The graph shows the vaccine doses reported daily to people around the world. Due to the spikes caused by the reporting delay, the line showing the 7-day rolling average for a given dose provides a clearer picture of whether the roll-out speed is accelerating or slowing.
The state of leading vaccines
The following table records the status of the leading COVID-19 vaccines, shows the authorizations for use in the United States and other light markets, and the prices in the purchase agreement information UNICEF compilation(If there is).
Pfizer/BioNTech and Moderna’s vaccines, clinical trial results show that they are more than 90% effective In the prevention of diseases, based on new technology It is possible to provide RNA sequences that make our own cells produce viral proteins to trigger an immune response.
The disadvantage is that these vaccines are more expensive than vaccines made by splicing the genetic material of the coronavirus into a banned version of another virus (such as those produced by the Anglo-Swedish company AstraZeneca). Based on Oxford University research, JohnsonAnd Russian Gamaria Institute.
Other leading vaccines are based on inactivated versions of the coronavirus, a long-term method of producing vaccines or protein subunits made from viruses.
Jeremy Singer-Vine provided coverage for this story.